Janssen can't conjure up enough patients for phase 1 prostate cancer study with ESSA AbbVie drops midphase psoriasis prospect over preclinical toxicology data, sinking partner's stock Long-suffering CytoDyn withdraws HIV approval application for leronlimab, blaming CRO Replay unveils eye-focused Eudora, its first of 4 HSV gene therapy companies coming down the line Santhera sends pulmonary drug to back of queue as DMD asset swallows funding Actinium’s radiotherapy spooks AML in elderly patients, prompting a sweet tooth for regulatory approval Y-mAbs' rare disease drug roundly rejected by FDA AdComm over weakness of single-arm trial Drug that acts on brain's dorsal raphe nucleus could rapidly treat depression | 